<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Mol Psychiatry</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Molecular psychiatry</journal-title></journal-title-group><issn pub-type="ppub">1359-4184</issn><issn pub-type="epub">1476-5578</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10231646</article-id><article-id pub-id-type="pmcid-ver">PMC10231646.1</article-id><article-id pub-id-type="pmcaid">10231646</article-id><article-id pub-id-type="pmcaiid">10231646</article-id><article-id pub-id-type="manuscript-id">NIHMS1899846</article-id><article-id pub-id-type="pmid">36123420</article-id><article-id pub-id-type="doi">10.1038/s41380-022-01736-y</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1899846</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1899846</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0902-4212</contrib-id><name name-style="western"><surname>Farokhnia</surname><given-names initials="M">Mehdi</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A13" ref-type="aff">13</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1408-7907</contrib-id><name name-style="western"><surname>Rentsch</surname><given-names initials="CT">Christopher T.</given-names></name><xref rid="A3" ref-type="aff">3</xref><xref rid="A4" ref-type="aff">4</xref><xref rid="A5" ref-type="aff">5</xref><xref rid="A13" ref-type="aff">13</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1996-8164</contrib-id><name name-style="western"><surname>Chuong</surname><given-names initials="V">Vicky</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A6" ref-type="aff">6</xref><xref rid="A13" ref-type="aff">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McGinn</surname><given-names initials="MA">M. Adrienne</given-names></name><xref rid="A6" ref-type="aff">6</xref><xref rid="A13" ref-type="aff">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Elvig</surname><given-names initials="SK">Sophie K.</given-names></name><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9290-6472</contrib-id><name name-style="western"><surname>Douglass</surname><given-names initials="EA">Eliza A.</given-names></name><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gonzalez</surname><given-names initials="LA">Luis A.</given-names></name><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sanfilippo</surname><given-names initials="JE">Jenna E.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5040-7966</contrib-id><name name-style="western"><surname>Marchette</surname><given-names initials="RCN">Renata C. N.</given-names></name><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tunstall</surname><given-names initials="BJ">Brendan J.</given-names></name><xref rid="A6" ref-type="aff">6</xref><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fiellin</surname><given-names initials="DA">David A.</given-names></name><xref rid="A4" ref-type="aff">4</xref><xref rid="A8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Koob</surname><given-names initials="GF">George F.</given-names></name><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0139-5502</contrib-id><name name-style="western"><surname>Justice</surname><given-names initials="AC">Amy C.</given-names></name><xref rid="A3" ref-type="aff">3</xref><xref rid="A4" ref-type="aff">4</xref><xref rid="A8" ref-type="aff">8</xref><xref rid="A14" ref-type="aff">14</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7284-8754</contrib-id><name name-style="western"><surname>Leggio</surname><given-names initials="L">Lorenzo</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A9" ref-type="aff">9</xref><xref rid="A10" ref-type="aff">10</xref><xref rid="A11" ref-type="aff">11</xref><xref rid="A12" ref-type="aff">12</xref><xref rid="A14" ref-type="aff">14</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8829-8627</contrib-id><name name-style="western"><surname>Vendruscolo</surname><given-names initials="LF">Leandro F.</given-names></name><xref rid="A6" ref-type="aff">6</xref><xref rid="A14" ref-type="aff">14</xref></contrib></contrib-group><aff id="A1"><label>1</label>Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, MD, USA</aff><aff id="A2"><label>2</label>Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA</aff><aff id="A3"><label>3</label>VA Connecticut Healthcare System, US Department of Veterans Affairs, West Haven, CT, USA.</aff><aff id="A4"><label>4</label>Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.</aff><aff id="A5"><label>5</label>Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.</aff><aff id="A6"><label>6</label>Neurobiology of Addiction Section, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.</aff><aff id="A7"><label>7</label>Department of Pharmacology, Addiction Science, and Toxicology, University of Tennessee Health Science Center, Memphis, TN, USA.</aff><aff id="A8"><label>8</label>Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, CT, USA.</aff><aff id="A9"><label>9</label>Medication Development Program, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.</aff><aff id="A10"><label>10</label>Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, Providence, RI, USA.</aff><aff id="A11"><label>11</label>Division of Addiction Medicine, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.</aff><aff id="A12"><label>12</label>Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA.</aff><aff id="A13"><label>13</label>These authors contributed equally: Mehdi Farokhnia, Christopher T. Rentsch, Vicky Chuong, M. Adrienne McGinn.</aff><aff id="A14"><label>14</label>These authors jointly supervised this work: Amy C. Justice, Lorenzo Leggio, Leandro F. Vendruscolo.</aff><author-notes><corresp id="CR1"><bold>Correspondence</bold> and requests for materials should be addressed to Lorenzo Leggio or Leandro F. Vendruscolo, <email>lorenzo.leggio@nih.gov</email>; <email>leandro.vendruscolo@nih.gov</email></corresp><fn fn-type="con" id="FN1"><p id="P1">AUTHOR CONTRIBUTIONS</p><p id="P2">MF and LL conceptualized the study. MF, CTR, VC, MAM, RCNM, BJT, GFK, ACJ, LL, and LFV designed the study and developed the data analysis plan. For the rodent studies, VC, MAM, SKE, EAD, and LAG conducted the experiments and RCNM, BJT, GFK, and LFV provided support. For the pharmacoepidemiology study, CTR managed and analyzed data and DAF and ACJ provided support. MF, CTR, VC, and MAM wrote the first draft of the manuscript and JES, LL, and LFV contributed to the first draft of the manuscript. All authors reviewed, provided feedback, and approved the final manuscript. GFK, ACJ, and LL provided funding for this study.</p></fn></author-notes><pub-date pub-type="ppub"><month>11</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>20</day><month>9</month><year>2022</year></pub-date><volume>27</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">436951</issue-id><fpage>4642</fpage><lpage>4652</lpage><pub-history><event event-type="nihms-submitted"><date><day>24</day><month>05</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>31</day><month>05</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>31</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 12:25:14.010"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><permissions><license><license-p><bold>Reprints and permission information</bold> is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/reprints">http://www.nature.com/reprints</ext-link></license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1899846.pdf"/><abstract id="ABS1"><p id="P3">Evidence suggests that spironolactone, a nonselective mineralocorticoid receptor (MR) antagonist, modulates alcohol seeking and consumption. Therefore, spironolactone may represent a novel pharmacotherapy for alcohol use disorder (AUD). In this study, we tested the effects of spironolactone in a mouse model of alcohol drinking (drinking-in-the-dark) and in a rat model of alcohol dependence (vapor exposure). We also investigated the association between spironolactone receipt for at least 60 continuous days and change in self-reported alcohol consumption, using the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C), in a pharmacoepidemiologic cohort study in the largest integrated healthcare system in the US. Spironolactone dose-dependently reduced the intake of sweetened or unsweetened alcohol solutions in male and female mice. No effects of spironolactone were observed on drinking of a sweet solution without alcohol, food or water intake, motor coordination, alcohol-induced ataxia, or blood alcohol levels. Spironolactone dose-dependently reduced operant alcohol self-administration in dependent and nondependent male and female rats. In humans, a greater reduction in alcohol consumption was observed among those who received spironolactone, compared to propensity score-matched individuals who did not receive spironolactone. The largest effects were among those who reported hazardous/heavy episodic alcohol consumption at baseline (AUDIT-C &#8805; 8) and those exposed to &#8805; 50 mg/day of spironolactone. These convergent findings across rodent and human studies demonstrate that spironolactone reduces alcohol use and support the hypothesis that this medication may be further studied as a novel pharmacotherapy for AUD.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>